-
Alloy Therapeutics Partners with Takeda on iPSC-Derived CAR-T and CAR-NK Therapies
•
US-based Alloy Therapeutics Inc. has announced a strategic partnership with Japan-headquartered Takeda Pharmaceutical Co., Ltd (TYO: 4502) to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). This collaboration aims to bolster the development of key therapies targeting solid and hematological…
-
AbbVie’s Elahere Receives EC Approval for FRα-Positive Ovarian Cancer Treatment
•
US-based AbbVie (NYSE: ABBV) has announced the European Commission (EC) approval for its antibody drug conjugate (ADC) Elahere (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. This approval marks Elahere as the first and…
-
ATLATL and Takeda Enter MoU to Collaborate on Early-Stage Drug Development and Innovation
•
ATLATL, an innovation incubator and global life science research and development (R&D) platform, has signed a cooperation memorandum of understanding (MoU) with Takeda (TYO: 4502). This partnership aims to jointly explore opportunities in early development, new technology application, and innovative company empowerment, with a focus on oncology, neuroscience, digestive, and…
-
Takeda Reports 5% YOY Revenue Growth and Upgrades Forecasts for Fiscal 2024
•
Takeda (TYO: 4502) has released its earnings results for the first half of fiscal year 2024, reporting a 5% year-on-year (YOY) increase in global revenues at constant exchange rates (CER), reaching JPY 2.38 trillion (USD 15.63 billion). The core operating profit margin expanded to 30.2%, marking a 2.2 percentage point…
-
HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales
•
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a USD 20 million milestone payment from its Japanese partner Takeda (TYO: 4502; NYSE: TAK), following the achievement of over USD 200 million in sales of Fruzaqla (fruquintinib) for metastatic colorectal cancer (CRC). Fruquintinib, a selective oral inhibitor…
-
Takeda Prepares to File Dengue Fever Vaccine for US Approval, Expanding Global Regulatory Reach
•
Takeda Pharmaceutical, a leading Japanese pharmaceutical company listed on the NYSE (NYSE: TAK), is reportedly preparing to submit its dengue fever vaccine for regulatory approval in the United States, according to the Nikkei Asian Review. At this juncture, specifics regarding the timing of the filing or the anticipated decision date…
-
Takeda’s Vonicog Alfa Receives NMPA Approval for Von Willebrand Disease Treatment in China
•
Takeda Pharmaceutical Company Limited (TYO: 4502 / NYSE: TAK), a leading Japanese pharmaceutical company, has announced that it has received marketing approval from China’s National Medical Products Administration (NMPA) for vonicog alfa, a recombinant von Willebrand factor (rVWF), for the on-demand treatment and control of bleeding events in adult patients…
-
Takeda to Slash 1,000 US Jobs as Part of Broader Restructuring Effort
•
Japanese pharmaceutical giant Takeda Pharmaceuticals (TYO: 4502 / NYSE: TAK) has confirmed reports from Nikkei that it is planning to eliminate approximately 1,000 positions in the United States. This move is part of a strategic downsizing that will see the closure of a research facility in San Diego, California, and…
-
Takeda Reports Q1 FY2024 Earnings with Growth in Key Therapies and New Launches
•
Japanese pharmaceutical company Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the first quarter of fiscal year 2024, ending June 30, 2024. The company reported a 2.1% increase in global sales year-on-year, reaching ¥1,208 billion ($7.85 billion) at constant exchange rates. Takeda’s Growth and Launch Product portfolio,…
-
Belief BioMed and Takeda’s Hemophilia B Gene Therapy BBM-H901 Accepted for NMPA Review
•
Belief BioMed Group (BBM), a Shanghai-based gene therapy specialist, and Takeda have announced that the National Medical Products Administration (NMPA) has accepted for review the New Drug Application (NDA) for BBM-H901, a gene therapy for hemophilia B. This development marks a significant milestone for the treatment, which is being designed…
-
Ascentage Pharma Receives USD 100 Million Option Rights Payment from Takeda
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has received a USD 100 million option rights payment from its Japanese partner Takeda (TYO: 4502), in accordance with an exclusive option agreement signed earlier last month. In June 2024, Takeda and Ascentage entered into an…
-
Takeda’s CEO Weber Eyes Further Partnerships with Chinese Biotechs Amid Innovation Surge
•
Takeda Pharmaceutical Co., (TYO: 4502, NYSE: TAK), a leading Japanese pharmaceutical company, is actively seeking potential partnerships with Chinese biotech firms, according to CEO Christophe Weber in a recent Bloomberg interview. Weber highlighted that despite finalizing two recent agreements with Chinese companies, Takeda is still “very open” to further collaborations,…
-
Takeda’s Fruquintinib for Metastatic Colorectal Cancer Receives European Commission Marketing Approval
•
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its partner Takeda (TYO: 4502, NYSE: TAK) has received marketing approval from the European Commission for fruquintinib, a treatment for adult patients with metastatic colorectal cancer (CRC) who have previously been treated with chemotherapy regimens based on fluorouracil, oxaliplatin, and…
-
Takeda’s Soticlestat Misses Primary Endpoints in Phase III Epilepsy Trials
•
Takeda Pharmaceutical Co., Ltd (TYO: 4502; NYSE: TAK), a leading Japanese pharmaceutical company, has announced that its drug candidate soticlestat did not meet the primary endpoints in two Phase III trials. The drug is currently under development for the treatment of two rare forms of epilepsy—Dravet syndrome and Lennox-Gastaut syndrome—and…
-
Takeda Secures Global Rights to Ascentage Pharma’s Olverembatinib Outside of China and Select Territories
•
Takeda Pharmaceuticals, a leading biopharmaceutical company based in Japan (TYO: 4502), has entered into an option agreement with China-based Ascentage Pharma (HKG: 6855), securing exclusive development and commercialization rights for olverembatinib, a third-generation BCR-ABL tyrosine kinase inhibitor (TKI), in markets outside of China, Hong Kong, Macau, Taiwan, and Russia. The…
-
Degron Therapeutics Partners with Takeda for Molecular Glue Degraders Development
•
Degron Therapeutics, a biopharmaceutical company based in China, has entered into a collaboration development and licensing agreement with Takeda (TYO: 4502), a leading pharmaceutical company in Japan. The partnership aims to discover and develop novel molecular glue degraders targeting oncology, neuroscience, and inflammation. According to the agreement, Degron Therapeutics will…
-
Nabla Bio Forges Partnerships with Top Pharma Companies to Tackle Challenging Drug Targets
•
Protein design specialist Nabla Bio has announced strategic collaborations with pharmaceutical giants AstraZeneca (AZ; NASDAQ: AZN), Bristol Myers Squibb (BMS; NYSE: BMY), and Takeda (NYSE: TAK). These partnerships underscore the biotech company’s commitment to leveraging its integrated AI and wet-lab technologies for the design of conformation- and target-selective antibody candidates.…
-
Takeda Strikes Deal with AC Immune for Global Rights to Alzheimer’s Immunotherapies
•
Takeda Pharmaceutical Company Limited (NYSE: TAK) has entered into an agreement with AC Immune SA (NASDAQ: ACIU), a Switzerland-based developer of advanced immunotherapies, to obtain an exclusive global license for the company’s active immunotherapies that target toxic forms of amyloid beta (Abeta). This strategic partnership positions Takeda at the forefront…
-
Takeda’s Fiscal 2023 Revenues Grow 1.5%, CEO Weber Forecasts 2025 Profitability After 2024 Dip
•
Takeda’s (TYO: 4502) annual report for the fiscal year ended March 31, 2024, has been released, showing a 1.5% year-on-year increase in global revenues at constant exchange rates (CER), reaching JPY 4.3 trillion (USD 27.4 billion). This growth was achieved despite a significant impact from the loss of exclusivity on…
-
HutchMed’s Partner Takeda Gets CHMP Nod for Fruquintinib as CRC Treatment in Europe
•
HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) has announced that its collaborator Takeda (TYO: 4502, NYSE: TAK) has received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the approval of fruquintinib for the treatment of adult patients with…
-
Takeda Exits Biotechnology Innovation Organization as Big Pharma Reevaluates Industry Groups
•
Japanese pharmaceutical giant Takeda (NYSE: TAK) has officially withdrawn its membership from the Biotechnology Innovation Organization (BIO), the world’s largest biotech trade association, according to Fierce Pharma. This move makes Takeda the fourth major company to leave BIO since December of the previous year, following the exits of Pfizer and…
-
Takeda and Astellas Join Forces with Sumitomo Mitsui to Launch Drug Discovery Joint Venture
•
Japanese pharmaceutical giants Takeda (NYSE: TAK) and Astellas (TSE: 4503) have joined hands with compatriot bank Sumitomo Mitsui to establish a joint venture (JV) aimed at nurturing drug discovery start-ups. The yet-to-be-named JV will leverage the pharmaceutical companies’ expertise to foster innovation in the early stages of drug development.- Flcube.com
-
Takeda Scores FDA Nod for Subcutaneous Vedolizumab to Treat Inflammatory Bowel Disease
•
The US Food and Drug Administration (FDA) has granted Takeda Pharmaceutical Company Limited (NYSE: TAK), a Japanese pharmaceutical company, registration authorization for a subcutaneous formulation of its alpha4beta7 integrin antagonist Entyvio (vedolizumab). This new formulation is intended for use as a maintenance therapy in patients with moderately to severely active…
-
Huadong Medicine Gets NMPA Approval for Clinical Trial of FRα-Targeting ADC Elahere
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for Elahere (mirvetuximab soravtansine), the company’s antibody drug conjugate (ADC) that targets folate receptor α (FRα). The study will evaluate Elahere as a…
-
Takeda’s Strategic Shift: China Becomes Integral to Global R&D Pipeline
•
Japan’s Takeda Pharmaceuticals (NYSE: TAK) has underscored its commitment to the Chinese market at this week’s Takeda R&D China Innovation Forum 2024 in Shanghai. The forum highlighted the integration of China into the company’s global research pipeline, with President Andy Plump announcing that Chinese sites are now participating in 100%…
-
Takeda Gains MHLW Approval for Adzynma, Targeting Rare Blood Disorder cTTP
•
Takeda Pharmaceutical Company (TYO: 4502) has secured regulatory approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its enzyme replacement therapy, Adzynma (apadamtase alfa), to treat congenital thrombotic thrombocytopenic purpura (cTTP) in patients aged 12 and older. cTTP is a rare and potentially life-threatening blood clotting disorder resulting…
-
FDA Grants Accelerated Approval for Takeda’s Iclusig in Newly Diagnosed Ph+ ALL
•
The U.S. Food and Drug Administration (FDA) has granted accelerated indication extension approval to Japan’s Takeda Pharmaceutical Company (TYO: 4502) for its tyrosine kinase inhibitor (TKI) Iclusig (ponatinib) in combination with chemotherapy for the treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This follows the drug’s previous…
-
Takeda Partners with Biological E to Boost Production of Dengue Vaccine QDenga
•
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has entered into an agreement with India-based Biological E (BE) with the aim of increasing production capacity for its dengue tetravalent vaccine, QDenga. This strategic partnership is part of Takeda’s broader plan to manufacture 100 million doses of the vaccine annually. QDenga,…
-
Takeda’s Recombinant Pig FVIII Drug for Acquired Hemophilia A Approved in China
•
The National Medical Products Administration (NMPA) website has indicated that Takeda (TYO: 4502)’s Obizur (susoctocog alfa), intended for on-demand treatment and control of bleeding events in adult patients with acquired hemophilia A, has received approval in China. This drug marks the first recombinant pig FVIII (rpFVIII) to be approved by…
-
Polpharma Biologics’ Biosimilar Candidate PB016 Shows Comparable Profiles to Takeda’s Entyvio
•
Polish biotechnology firm Polpharma Biologics has announced positive results from a comparability study for its late-stage biosimilar candidate PB016, which references Takeda’s (TYO: 4502) inflammatory bowel disease (IBD) blockbuster Entyvio (vedolizumab). The study’s data indicate that PB016 demonstrates similar pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and safety profiles compared to the…
-
FDA Approves Takeda’s Eohilia as First Oral Therapy for Eosinophilic Esophagitis in Patients Aged 11 and Up
•
The U.S. Food and Drug Administration (FDA) has granted approval to Takeda Pharmaceutical Company (TYO: 4502)’s Eohilia (budesonide oral suspension) for the treatment of eosinophilic esophagitis (EoE). This marks Eohilia as the first and currently only oral therapy available for EoE patients aged 11 and older. Previously, Novartis (NYSE: NVS)’s…
-
Takeda Secures Rights to Protagonist Therapeutics’ Rusfertide in Landmark Deal
•
Takeda Pharmaceuticals Company Limited (TYO: 4502) has announced a significant expansion of its hematology portfolio with the acquisition of partial commercial rights to Protagonist Therapeutics Inc.’s investigational drug rusfertide in the U.S., and full rights outside the country. The agreement entails an upfront payment of USD 300 million to the…
-
European Commission Approves Takeda’s Hyqvia for Chronic Inflammatory Demyelinating Polyneuropathy
•
The European Commission (EC) has granted regulatory approval to Takeda Pharmaceutical Company Limited (TYO: 4502) for its plasma-derived therapy Hyqvia (human immune globulin infusion 10% with recombinant human hyaluronidase) as a maintenance treatment for chronic inflammatory demyelinating polyneuropathy (CIDP). This follows a similar indication extension for the subcutaneous drug in…
-
Takeda’s Gammagard Liquid Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy
•
The US Food and Drug Administration (FDA) has granted regulatory approval for Takeda’s (TYO: 4502) plasma-derived therapy Gammagard Liquid, a human immune globulin, for use as induction therapy and treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. This decision is supported by clinical data demonstrating that the intravenous immunoglobulin…
-
Takeda’s Hyqvia Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy
•
Japanese pharmaceutical company Takeda (TYO: 4502) has received an indication extension approval from the US Food and Drug Administration (FDA) for its plasma-derived therapy Hyqvia (human immunoglobulin 10%). The therapy is now approved for use as a maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). Initially approved in the US…
-
Takeda Ends Gene Therapy Collaboration with JCR Pharmaceuticals, Returns IP
•
Takeda Pharmaceuticals Company Limited (TYO: 4502) has announced the termination of a 2022 collaboration agreement with fellow Japanese firm JCR Pharmaceuticals Co., Ltd. (TYO: 4552) for the development of gene therapies. As a result of the termination, Takeda will return all research outcomes and patents to JCR. This strategic decision…
-
Takeda’s Livtencity Receives NMPA Approval, a First in China for CMV Infection Treatment
•
Japanese pharmaceutical company Takeda (TYO: 4502) has received its first market approval from China’s National Medical Products Administration (NMPA) for Livtencity (maribavir), a significant milestone for the treatment of adult patients with cytomegalovirus (CMV) infection/disease following hematopoietic stem cell transplantation or solid organ transplantation. The drug is particularly indicated for…
-
Takeda Reinforces Takeda Spark Incubator Program with Expanded Partnerships in China
•
Takeda (TYO: 4502) has reportedly renewed and expanded a series of partnerships to bolster its Takeda Spark incubator program in China. Initially launched in 2021, the incubator program partners with consulting firms PricewaterhouseCoopers and Accenture, tech giant Amazon Web Services, and the investment fund Shanghai Biopharmaceutical Innovative Transformation Fund. Takeda…
-
Takeda’s Takecab Receives NMPA Approval for Helicobacter pylori Eradication in China
•
Takeda (TYO: 4502), a Japan-based pharmaceutical company, has announced that it has received another indication approval from China’s National Medical Products Administration (NMPA) for its drug Takecab (vonoprazan) to eradicate Helicobacter pylori (HP) when combined with appropriate antibiotics. The vonoprazan-based quadruple regimen, which includes bismuth, is the first of its…
-
US FDA Approves HutchMed and Takeda’s Fruzaqla for Metastatic Colorectal Cancer Treatment
•
The US Food and Drug Administration (FDA) has granted approval to HutchMed (NASDAQ: HCM) and its partner Takeda (NYSE: TAK, TYO: 4502) for their oral tyrosine kinase inhibitor Fruzaqla (fruquintinib), marking the second approval this year for a China-developed innovative drug. The drug is indicated for adult patients with previously…
-
Takeda Partners with New Horizon Health Technology to Manage Helicobacter pylori in China
•
At the 6th China International Import Expo (CIIE) in Shanghai, Japan-based Takeda has inked a partnership with China-based New Horizon Health Technology Co., Ltd (HKG: 6606), a leading cancer diagnostics developer. The collaboration aims to develop a comprehensive management solution for Helicobacter pylori patients in China, underscoring Takeda’s (TYO: 4502)…
-
Novartis Seeks Access to Takeda’s Business Records Over Confidentiality Concerns
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) filed a complaint with a US court last week, seeking discovery to gain access to certain business records of Japan-based Takeda (TYO: 4502). Novartis aims to determine whether Takeda has potentially benefited from confidential documents that may have been inappropriately transferred by a former…
-
Takeda’s Global Revenues Grow: Strong Performance in Plasma Therapies and Gastroenterology
•
Japan-based pharmaceutical giant Takeda (TYO: 4502) has released its financial results for the 6-month period ending September 30, 2023, with global revenues hitting JPY 2.1 trillion (USD 14.0 billion). This represents a 6.4% year-on-year (YOY) increase in reported terms, or a more modest 1.4% growth at constant exchange rates (CER).…
-
Huadong Medicine’s Elahere Accepted for NMPA Review in China for Ovarian Cancer Treatment
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration (NMPA) has accepted the market filing for its antibody drug conjugate (ADC) Elahere (mirvetuximab soravtansine), targeting folate receptor α (FRα). This marks a significant step towards making the treatment available for patients in China. Acquisition…
-
Belief BioMed Partners with Takeda for BBM-H901 Commercialization in Asia
•
Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced a strategic partnership with Japan’s Takeda Pharmaceutical Company (TYO: 4502), granting Takeda commercialization rights for its investigational product, BBM-H901. This agreement encompasses the territories of mainland China, Hong Kong, and Macau. Financial details of the partnership have not been disclosed.…
-
HutchMed and Takeda Submit Fruquintinib NDA for Metastatic CRC in Japan
•
China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced that its partner Takeda (TYO: 4502) has submitted a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for the approval of fruquintinib as a treatment for adult patients with previously treated metastatic colorectal cancer (CRC).…
-
Takeda Initiates Global Withdrawal of Exkivity Following Phase III Trial Results
•
Japan-based Takeda (TYO: 4502) has announced the voluntary global withdrawal of its tyrosine kinase inhibitor (TKI) Exkivity (mobocertinib) from the U.S. market. This decision comes after a Phase III confirmatory trial failed to meet its primary efficacy endpoint. Exkivity, a first-in-class therapy, had previously received conditional approvals worldwide as a…
-
Takeda Receives FDA Approval for Subcutaneous Entyvio as UC Maintenance Therapy
•
The US Food and Drug Administration (FDA) has granted Japan’s Takeda Pharmaceuticals (TYO: 4502) regulatory approval for the subcutaneous version of its alpha4beta7 integrin inhibitor, Entyvio (vedolizumab), as a maintenance therapy for adults with moderately to severely active ulcerative colitis (UC) following induction therapy with intravenous Entyvio. This decision comes…
-
FDA Accepts Takeda’s Filing for Subcutaneous Entyvio as Maintenance Therapy for Crohn’s Disease
•
The US Food and Drug Administration (FDA) has accepted a filing from Japan-based Takeda (TYO: 4502) for a subcutaneous version of the alpha4beta7 integrin inhibitor Entyvio (vedolizumab). This new formulation is intended as a maintenance therapy for adult patients with moderately to severely active Crohn’s disease (CD) who have been…
